Susan Wu
YOU?
Author Swipe
View article: Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion
Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion Open
Introduction: Immune checkpoint inhibitors have been relatively ineffective in acute myeloid leukemias (AML), likely due to immune tolerance induced by the systemic disease as well as the chronic immune suppression after cytotoxic therapie…
View article: Supplementary Table 1 from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma
Supplementary Table 1 from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma Open
Supplemental Table 1 shows the univariate analysis of the association between patient and clinical factors and radiation therapy (RT) receipt in adolescents and young adults (AYAs) with Hodgkin Lymphoma
View article: Data from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma
Data from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma Open
Background:Hodgkin lymphoma has excellent survival rates in adolescents and young adults (AYA, diagnosed between ages 15 and 39 years). However, survivors are at risk of treatment-related late effects. Whereas radiotherapy (RT) de-escalati…
View article: Supplemental Figure 1 from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma
Supplemental Figure 1 from Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma Open
. Participant exclusions and the resulting numbers of included participants are shown in this consort diagram.
View article: Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma
Trends in Radiation Use from 2004 to 2020 among Adolescents and Young Adults with Hodgkin Lymphoma Open
Background: Hodgkin lymphoma has excellent survival rates in adolescents and young adults (AYA, diagnosed between ages 15 and 39 years). However, survivors are at risk of treatment-related late effects. Whereas radiotherapy (RT) de-escalat…
View article: Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study
Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study Open
Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refr…
View article: Successful Deep Sedation with Remimazolam and Alfentanil in a Child Susceptible to Malignant Hyperthermia: A Case Report
Successful Deep Sedation with Remimazolam and Alfentanil in a Child Susceptible to Malignant Hyperthermia: A Case Report Open
Background Malignant hyperthermia (MH) is a life-threatening autosomal-dominant disorder caused by mutations in the ryanodine receptor 1 (RYR1) gene, leading to calcium dysregulation in skeletal muscle. Patients with genetically confirmed …
View article: Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas Open
Background Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and treatment …
View article: Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)
Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT) Open
Background: Large cell transformation (LCT) occurs in about 20-50% of mycosis fungoides (MF) cases. LCT is associated with a poor prognosis with a median survival of 3.6 years. Most patients experience a relapsed, refractory disease course…
View article: Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases
Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases Open
Introduction:Large cell transformation (LCT) of mycosis fungoides/Sezary syndrome (MF/SS) is associated with an aggressive clinical course and poor overall survival (OS). Patients and methods: We retrospectively analyzed 2861 MF/SS patient…
View article: Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation? Open
In this Western Hemisphere cohort of early-stage ENKTCL patients treated with CMT, ENI may have a potential clinical benefit, particularly in patients who are treated with non-asparaginase-containing CMT, such as in patients treated with r…
View article: Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung
Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung Open
ULDRT, given in a response-adapted approach, is effective and well tolerated by patients with lung MALT.
View article: Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs Open
Background Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) organs is rare, and real-world outcomes after combined modality therapy (CMT) with systemic therapy (ST) and radiotherapy (RT) are not well-characterized,…
View article: Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma Open
Importance Radiation therapy to doses of 24 to 36 Gy is currently used to treat indolent B-cell lymphoma of the ocular adnexa; however, ocular adverse effects are common. Objective To determine if a response-adapted radiation therapy strat…
View article: Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases
Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases Open
Primary human hepatocyte (PHH) transplantation is a promising alternative to liver transplantation, whereby liver function could be restored by partial repopulation of the diseased organ with healthy cells. However, currently PHH engraftme…
View article: Motion Management: The Road Map to Accurate Radiation Treatment Delivery
Motion Management: The Road Map to Accurate Radiation Treatment Delivery Open
Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatme…
View article: Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma
Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Gastric MALT Lymphoma Open
Introduction Definitive treatment for early-stage gastric MALT (mucosa-associated lymphoid tissue) lymphoma typically includes radiation therapy (RT) to doses of 24-30 Gy. Given the favorable prognosis of this disease, there is considerabl…
View article: The positive impact of journaling on adolescents with cystic fibrosis
The positive impact of journaling on adolescents with cystic fibrosis Open
Background Individuals with cystic fibrosis (CF) often have psychological difficulties on top of their medically complex care, such as anxiety, depression, and medical mistrust. These have been shown to be associated with worse adherence, …
View article: Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma Open
In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). …
View article: The Positive Impact of Journaling on Adolescents with Cystic Fibrosis
The Positive Impact of Journaling on Adolescents with Cystic Fibrosis Open
Background Individuals with cystic fibrosis (CF) often have psychological difficulties on top of their medically complex care, such as anxiety, depression, and medical mistrust. These have been shown to be associated with worse adherence, …